115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Association of DAZL expression with risk of recurrence in clinical stage 1 testicular germ cell tumors
    Meeting Abstract

    Tewari, A.; Hamid, A.; Huang, J. M.; Zhong, C.; Xie, W.; Rothmann, E.; Nicholls, P.; Walk, N.; Brcic, I.; Terbuch, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pre-orchiectomy serum miRNA-371a-3p and 372-3p levels in men with clinically localized testicular masses
    Meeting Abstract

    Baky, F.; Matulewicz, R.; Knezevic, A.; Ye, F.; Williams, B.; Bromberg, M.; Benfante, N.; Valentino, A.; Kantor, R.; So, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC)
    Meeting Abstract

    Labaki, C.; Alchoueiry, M.; Bi, K. V.; Zhang, L.; Hobeika, C.; Bakouny, Z.; El Ahmar, N.; Matar, S.; Priolo, C.; Khabibullin, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting
    Meeting Abstract

    Shah, N. J.; Bhattacharya, R.; Ning, N.; Shinde, R.; Schmier, J.; Tan, M. L. D.; Lemasters, T.; Sundaram, M.; Perini, R. F.; Motzer, R. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy
    Meeting Abstract

    Zang, P. D.; Twardowski, P.; Chen, D. L.; Hall, E. T.; Hays, D.; Wilson, I.; Schmiedehausen, K.; Ferris, M.; Le, W.; Postow, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world data on treatment of chromophobe renal cell carcinoma
    Meeting Abstract

    Battle, D.; Griffith, M.; Msaouel, P.; Voss, M. H.; Staehler, M. D.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save